Edition:
United States

Basilea Pharmaceutica AG (BPMUF.PK)

BPMUF.PK on OTC Markets Group

92.55USD
--
Change (% chg)

-- (--)
Prev Close
$92.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
131
52-wk High
$92.55
52-wk Low
$62.05

Latest Key Developments (Source: Significant Developments)

Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million
Monday, 20 Feb 2017 01:15am EST 

Basilea Pharmaceutica AG : In 2017, Basilea will further advance clinical development of its oncology drug candidates and expects to complete dose-escalation in bal101553's phase 1/2a studies and bal 3833's phase 1 study . Product sales of 7.1 million Swiss francs ($7.08 million) in europe and 7.3 million francs royalties received on 2016 Cresemba US sales . 289 million francs cash and financial investments at 2016 year-end . FY net loss 51.3 million francs versus 61.6 million francs year ago .Sales for 2016 full year of 7.1 million francs in Europe.  Full Article

MedCap unit to distribute Basilea's products in Scandinavia
Tuesday, 20 Sep 2016 02:38am EDT 

MedCap AB (publ) : Says its unit Unimedic Pharma AB has entered into licensing and distribution agreement with Basilea Pharmaceutica Ltd .Agreement is for distribution of Basilea's products in Sweden, Denmark, Norway and Finland.  Full Article

Basilea Pharmaceutica: distribution agreement with Hikma for Cresemba in MENA region
Wednesday, 17 Aug 2016 01:15am EDT 

Basilea Pharmaceutica AG :Basilea announces distribution agreement with Hikma for Cresemba (isavuconazole) in the MENA region.  Full Article

Basilea Pharmaceutica H1 net loss narrows to CHF 27.9 million
Monday, 15 Aug 2016 01:15am EDT 

Basilea Pharmaceutica AG : Contract revenue in first half-year of 2016 amounted to 27.8 million Swiss francs ($28.50 million) (H1 2015: 24.4 million francs) . In H1 2016, operating loss amounted to 24.8 million francs, compared to 30.0 million francs in H1 2015 . H1 2016 product revenue amounted to 1.9 million francs (H1 2015: 0 million francs) . Total operating income in H1 2016 including sales amounted to 29.7 million francs (H1 2015: 25.0 million francs) . H1 net loss amounted to 27.9 million francs (H1 2015: 30.1 million francs) .Confirms guidance for total operating expenses for 2016 of approximately 9 - 10 million francs on average per month and average operating loss in 2016 of approximately 4 - 5 million francs per month.  Full Article

Basilea Pharmaceutica: CRESEMBA (isavuconazole) launched in Italy
Monday, 27 Jun 2016 01:15am EDT 

Basilea Pharmaceutica AG :Basilea's antifungal CRESEMBA (isavuconazole) launched in Italy.  Full Article

Basilea Pharmaceutica presents data on clinical oncology programs BAL101553 and BAL3833
Thursday, 21 Apr 2016 01:15am EDT 

Basilea Pharmaceutica AG:Reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting.Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment.PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models.  Full Article

Basilea Pharmaceutica wins contract by BARDA of up to $100 mln funding for Ceftobiprole phase 3 program
Wednesday, 20 Apr 2016 01:15am EDT 

Basilea Pharmaceutica AG:Basilea awarded contract by BARDA of up to $100 million funding for Ceftobiprole phase 3 program.  Full Article

Basilea Pharmaceutica nominates Domenico Scala as new chairman of board​
Tuesday, 15 Mar 2016 02:15am EDT 

Basilea Pharmaceutica AG:Martin Nicklasson has determined not to stand for re-election as chairman but will stand for re-election as member of board.​Domenico Scala nominated as new chairman of board​.  Full Article

Basilea Pharmaceutica launches senior convertible bond issue, intends to withdraw U.S. IPO plans
Wednesday, 9 Dec 2015 01:15am EST 

Basilea Pharmaceutica AG:Launches a senior convertible bond issue.Launch of 175 million Swiss francs senior unsecured convertible bonds due 2022 with possibility of Basilea to increase by a maximum of 25 million francs to 200 million‍ francs.Bonds are expected to carry a coupon of between 2.75 pct and 3.50 pct per annum​ ‍.Payment and settlement of bonds is expected on or about Dec. 23.Intends to withdraw its previously announced F-1 public offering of common shares in U.S. in form of American depository shares following pricing of convertible bond.  Full Article

Basilea Pharmaceutica says EC maintained isavuconazole's orphan drug status
Friday, 23 Oct 2015 01:15am EDT 

Basilea Pharmaceutica AG:Announces that European Commission maintained isavuconazole's orphan drug status.Says isavuconazole will benefit from ten years of market exclusivity associated with orphan medicinal product status in European Union.  Full Article

More From Around the Web

BRIEF-Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million

* In 2017, Basilea will further advance clinical development of its oncology drug candidates and expects to complete dose-escalation in bal101553's phase 1/2a studies and bal 3833's phase 1 study